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Role of Endothelin-1 in Exposure to High Altitude
Acute Mountain Sickness and Endothelin-1 (ACME-1) Study
Pietro Amedeo Modesti, MD, PhD; Simone Vanni, MD, PhD; Marco Morabito, PhD;
Alessandra Modesti, BS, PhD; Matilde Marchetta, BS; Tania Gamberi, BS, PhD; Francesco Sofi, MD, PhD;
Giulio Savia, MD; Giuseppe Mancia, MD; Gian Franco Gensini, MD; Gianfranco Parati, MD, PhD
Background—The degree of pulmonary hypertension in healthy subjects exposed to acute hypobaric hypoxia at high
altitude was found to be related to increased plasma endothelin (ET)-1. The aim of the present study was to investigate
the effects of ET-1 antagonism on pulmonary hypertension, renal water, and sodium balance under acute and prolonged
exposure to high-altitude–associated hypoxia.
Methods and Results—In a double-blind fashion, healthy volunteers were randomly assigned to receive bosentan (62.5 mg
for 1 day and 125 mg for the following 2 days; n10) or placebo (n10) at sea level and after rapid ascent to high
altitude (4559 m). At sea level, bosentan did not induce any significant changes in hemodynamic or renal parameters.
At altitude, bosentan induced a significant reduction of systolic pulmonary artery pressure (217 versus 317 mm Hg,
P0.03) and a mild increase in arterial oxygen saturation versus placebo after just 1 day of treatment. However, both
urinary volume and free water clearance (H2OCl/glomerular filtration rate) were significantly reduced versus placebo
after 2 days of ET-1 antagonism (1100200 versus 1610590 mL; 6.73.5 versus 1.84.8 mL/min, P0.05
versus placebo for both). Sodium clearance and segmental tubular function were not significantly affected by bosentan
administration.
Conclusions—The present results indicate that the early beneficial effect of ET-1 antagonism on pulmonary blood pressure
is followed by an impairment in volume adaptation. These findings must be considered for the prevention and treatment
of acute mountain sickness. (Circulation. 2006;114:1410-1416.)
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Hypoxia during ascent to high altitude is responsiblefor an increase in pulmonary artery pressure.1,2 The
increased venular tone with increased capillary pressure
that follows rapid ascent to high altitude without adequate
acclimatization3 may contribute to force liquid across the
endothelial barrier into the interstitial space, which may
contribute to respiratory problems in this condition. Be-
cause tens of thousands of tourists travel to a variety of
high-altitude destinations around the world on a yearly
basis, the search for new strategies to prevent and treat
high-altitude–induced pulmonary hypertension is now con-
sidered a priority.4 The acute increase in pulmonary
pressure in mountaineers was found to be closely related to
an increased plasma concentration of endothelin (ET)-1.3,5
Because of the reported efficacy of ET-1 antagonism in
patients with pulmonary hypertension, the use of ET-1
receptor blockade at high altitudes might be considered.6 A
second relevant component of adaptation to altitude is an
increase in urinary volume, associated with a reduced renal
sensitivity to arginine vasopressin (AVP).7 Recent studies
revealed that the lack of increase in urinary volume and
free water clearance has a relevant prognostic value for the
onset of acute mountain sickness (AMS) in mountaineers
reaching a high altitude (4880 m).8 ET-1 is produced in the
kidney, where it functionally antagonizes AVP.9,10 Al-
though exposure of healthy subjects to normobaric hypoxia
was found to enhance ET-1 urinary excretion,11 the func-
tional role of ET-1 in renal adaptation at high altitudes is
unknown.
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We therefore designed the present placebo-controlled
study to investigate the effects of bosentan, a mixed ET
receptor A and B (ETA/ETB) antagonist, on pulmonary
hemodynamic and renal function during the 4 days after
arrival at the research laboratory on Monte Rosa, the Regina
Margherita hut (Italian Alps, altitude 4559 m).
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Methods
Subjects and Study Design
Twenty healthy adult volunteers (17 men and 3 women, 32 to 53
years old) with past experience in mountain hiking, nonacclimatized
and without specific training, were recruited by word of mouth.
Smoking and medication use were exclusion criteria for study
participation.
Two to 4 weeks before ascension, all subjects underwent baseline
investigations at low altitude (50 m above sea level; barometric
pressure 772 mm Hg). At least 4 days before the study, subjects were
instructed to restrict their normal diet to avoid salty and spicy meals,
as well as the addition of salt to cooked foods. Subjects were also
instructed to avoid strenuous physical activity and alcohol- and
caffeine-containing drinks and to have at least 6 hours of sleep per
night. Furthermore, they were instructed to fast for 8 hours before the
experiment and to use passive transportation to the laboratory to
minimize physical activity during the study days.
On the first experimental day, the subjects underwent laboratory
investigations with echocardiographic measurements. Subjects were
then randomized to receive bosentan (Actelion, Ltd, Basel, Switzer-
land; 62.5 mg twice daily on day 1 and then 125 mg twice daily on
days 2 and 3, n10) or matching placebo (n10),12 being blinded to
the assigned treatment. Carbolithium (600 mg/d) was also adminis-
tered to all subjects to investigate proximal tubule reabsorption.
Echocardiography, blood sampling, and urine collection were then
repeated by the same physicians on the following 3 consecutive days.
The same protocol of drug administration and measurements was
then performed at altitude. All subjects ascended in less than 24
hours from Alagna Valsesia (Vercelli, Italy; altitude 1130 m) to a
research laboratory on Monte Rosa, the Regina Margherita hut
(altitude 4559 m; average barometric pressure 435 mm Hg), with an
overnight stay at the Gnifetti hut (altitude 3611 m). After a first night
at 4559 m, the subjects underwent laboratory investigations with
echocardiographic measurements. Subjects received bosentan or
matching placebo and carbolithium following the same protocol for
drug administration and data collection as at sea level. At altitude, all
subjects ate the same standard diet provided by the Regina Margh-
erita hut staff, with the recommendation to avoid the addition of salt
to cooked foods. Food and water intake were ad libitum. All other
instructions were identical to those at sea level.
Ascent was directly supervised by investigators. The investigators
continuously monitored the subjects for evidence of high-altitude
pulmonary edema (HAPE; defined as severe cough, dyspnea at rest,
cyanosis, and rales) or high-altitude cerebral edema (defined as
ataxia, altered consciousness, uncontrolled physical movements,
nausea, vomiting, or loss of consciousness). Immediate evacuation
and treatment with dexamethasone and oxygen were available for
such an occurrence. A standardized questionnaire for the clinical
assessment of AMS (Lake Louise score) was completed daily.13
All subjects were requested to give informed written consent to
participate in the study, in strict compliance with the Helsinki
Declaration. Experimental protocol and informed consent forms
were approved by the ethics committee of the Azienda Ospedaliera
Careggi (protocol 211/04).
Doppler Echocardiography
Mean and systolic pulmonary artery pressure were calculated daily
by color Doppler echocardiography (CARIS PLUS, ESAOTE Bio-
medica, Florence, Italy) based on the time to peak velocity of the
pulmonary artery Doppler velocity curve in short-axis view and on
the velocity of the tricuspid regurgitant jet and the respiratory
variation in inferior vena cava size, as an estimate of right atrial
pressure.14 To calculate the transtricuspid pressure gradient, a
modified Bernoulli equation was used in which transtricuspid pres-
sure equals 4 times the square of the tricuspid jet velocity.
The recordings were stored on VHS videotape for analysis by an
investigator who was unaware of the study procedures. All reported
values represent the mean of 2 measurements.
General Procedures and Collection of
Biological Samples
Systemic blood pressure, heart rate (ECG), and hemoglobin oxygen
saturation (pulse oximeter attached to a fingertip) were measured at
8 AM. Then, plasma and urine samples were collected. Blood samples
(25 mL/d) were drawn from subjects in the supine position from an
antecubital vein for assay of ET-1, glucose, urea, creatinine, Na, K,
Li, and osmolality. The samples were immediately put on ice and
then centrifuged at 3000 rpm for 10 minutes. Simultaneously, urine
samples for assay of ET-1, creatinine, Na, K, Cl, Li, and osmolality
were separated from the daily urine collection (40 mL). Plasma,
serum, and urine samples were then snap-frozen in liquid nitrogen
and stored at 20°C until their return to the laboratory.
Analytical Methods and Calculations
Plasma and urine were assayed for electrolytes (Na, K, and Li) with
an ion-sensitive electrode (Instrumentation Beckmann Astra, Brea,
Calif) and for creatinine with the Jaffe reaction (Instrumentation
Beckmann Astra).9 Glomerular filtration rate (GFR) was estimated
by the clearance of endogenous creatinine. Free water clearance
(H2OCl) was calculated as:
(1) H2OCl1UosmPosmV
where Uosm (mOsm/L H2O) and Posm (mOsm/L H2O) are the simul-
taneous urinary and plasma osmolalities, respectively, and V (mL/
min) is the simultaneous rate of urinary volume flow.
Osmolar clearance (OsmCl), sodium clearance (NaCl), lithium
clearance (LiCl), and creatinine clearance (CrCl) were calculated
with standard formula:
(2) clearanceUVP
where U and P are the simultaneous urinary and plasma concentra-
tions, respectively, and V (mL/min) is the simultaneous rate of
urinary volume flow. The LiCl is a measure of fluid delivery from
the proximal tubule to the loop of Henle. Fractional proximal and
distal sodium reabsorption rates were calculated as:
(3) Fractional proximal sodium reabsorption rateGFRLiClGFR
and
(4) Fractional distal sodium reabsorption rateLiClNaClLiCl
ET-1 Assay
ET-1 was extracted from both plasma and urine samples by Sep-Pak
Cartridge C18 PLUS columns (catalog No. 023635, Waters Corpo-
ration, Milford, Mass) and assayed by radioimmunoassay with
polyclonal rabbit anti-ET-1 serum (catalog No. S2024, Bachem-
Peninsula, San Carlos, Calif), as described previously.9,15–17 The
minimum detectable ET-1 amount was 0.1 pg.
Statistical Analysis
The sample size was calculated assuming an increase in pulmonary
arterial pressure of 6018% at 4559 m versus low-altitude values. A
sample size of 20 patients with equal allocation to bosentan or
placebo offered 80% power to detect a 50% reduction of the
pulmonary pressure increase with bosentan compared with placebo.
The error level was set at 5%.
Twenty-five subjects were contacted. Three subjects did not
accept our invitation, and 2 subjects were deemed ineligible because
of heavy smoking and arterial hypertension that required drug
treatment. The study at 4559 m was not completed by request of 1
subject in the placebo group after the examination on day 2.
The statistical analysis was performed with the SPSS software
package (SPSS Inc, Chicago, Ill). A 2-way repeated-measures
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ANOVA was used to compare differences between low and high
altitude and the 2 treatment groups. A random-effects linear regres-
sion model, which takes into account the lack of independence of a
subject’s measurements across time in the placebo group, was used.
This intrasubject correlation was modeled by a random intercept
effect, and parameters were estimated by the maximum likelihood
method. Coefficient estimate () and standard error were used for
data presentation. A probability value below 0.05 was set as the level
of minimum statistical significance.
The authors had full access to the data and take full responsibility
for their integrity. All authors have read and agree to the manuscript
as written.
Results
Clinical Effects of High Altitude
On the first day at Regina Margherita hut, before the
beginning of treatment (day 0), all subjects scored 3 or more
points on the Lake Louise assessment (6.43.1 and 7.73.2
in the placebo and bosentan-treated group, respectively).
However, the symptoms thereafter subsided, and the Lake
Louise score decreased in both the placebo and bosentan-
treated groups, remaining less than 2 on day 2 and day 3 in
the individual subjects (Table 1). Bosentan administration did
not affect either the Lake Louise score or systemic hemody-
namics (Table 1). Neither side effects nor adverse events
were observed in treated subjects either at altitude or at sea
level. A significant increase in both plasma concentration and
urinary ET-1 daily excretion was found in both groups versus
sea level (Figure 1).
ET-1 Antagonism and Pulmonary Adaptation
to Altitude
On arrival at Regina Margherita hut (day 0), subjects given
placebo showed a decrease in arterial oxygen saturation to
786% (P0.05 versus sea level) with a simultaneous
increase in systolic pulmonary artery pressure from 162 to
346 mm Hg (P0.05; Figure 2). The reduced arterial
oxygen saturation and the increased systolic pulmonary artery
pressure were maintained for 2 days, with a significant
increase and reduction, respectively, in these parameters at
the third day at altitude only (826% and 277 mm Hg; both
P0.05 versus day 0; Figure 2). Arterial oxygen saturation
was inversely related to systolic pulmonary artery pressure
(r0.654, P0.001; Figure 3), which was also directly
related to ET-1 plasma concentration (r0.582, P0.001;
Figure 3). These relationships were confirmed even after
taking into account multiple observations per subject, with
TABLE 1. Lake Louise Score and Systemic and Pulmonary Hemodynamics in
Subjects Assigned to Bosentan or Placebo-Treated Group at Sea Level and
High Altitude
High Altitude
Sea Level Day 0 Day 1 Day 2 Day 3
Lake Louise score
Placebo 0 6.43.1 2.22.0 1.20.9 10.8
Bosentan 0 7.73.2 2.71.6 1.10.7 0.60.8
Systolic blood pressure, mm Hg
Placebo 1189 12515 12628 12620 13123
Bosentan 1168 12514 13119 12810 12812
Diastolic blood pressure, mm Hg
Placebo 706 829 826 8218 8113
Bosentan 697 7911 7712 8112 8310
Heart rate, bpm
Placebo 663 847 807 776 767
Bosentan 673 867 815 8110 805
Arterial oxygen saturation, %
Placebo 1001 786 786 826 824
Bosentan 1001 757 814* 816 818
Systolic pulmonary artery pressure, mm Hg
Placebo 162 346 317 277 216
Bosentan 152 349 217* 197* 198
*P0.05 vs placebo.
Figure 1. Plasma concentration and urinary ET-1 daily excretion
at sea level (S.L.) and during exposure to high altitude (days 0,
1, 2, and 3) in bosentan- () or placebo-treated () group.
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the random-effects linear regression model, in the placebo
group (81.77.72, P0.0001 for oxygen saturation;
4.320.30, P0.001 for plasma ET-1).
In bosentan-treated subjects, systolic pulmonary artery
pressure at altitude was significantly reduced compared with
the placebo group even after just 1 day of treatment (day 1:
217 versus 317 mm Hg, P0.03). A simultaneous mild
increase in arterial oxygen saturation on day 1 was observed
(P0.05 versus day 0; Figure 2). On day 2, arterial oxygen
saturation was comparable in the 2 groups (826% versus
816%; Figure 2).
Renal Effects of ET-1 Antagonism
At altitude, 24-hour urinary volume (in milliliters) in the
placebo group increased by 40% and 59% versus sea level on
day 0 and day 1, respectively, then progressively decreased
and normalized on day 3 (Figure 4). On day 1, the enhanced
urine output was associated with a significant 10-fold change
in free water clearance versus sea level (Figure 4), with no
significant increases in sodium clearance (Figure 4) or lith-
ium clearance (Table 2). Likewise, the investigation of
fractional sodium reabsorption revealed no changes in abso-
lute and fractional proximal and distal sodium reabsorption
rates (Table 2). No significant changes in body weight
compared with sea level were found.
In bosentan-treated subjects, 24-hour urine output was
significantly lower than in the placebo group on days 1 and 2
(Figure 4). The lower urinary volume was associated with a
significant reduction in free water clearance in the bosentan
group compared with day 0 and with the placebo group
(P0.01 at day 2; Figure 4). Conversely, sodium clearance
(Figure 4), lithium clearance, and absolute and fractional
proximal and distal sodium reabsorption rates did not differ
between groups (Table 2).
Discussion
The present findings demonstrate for the first time that the use
of a mixed ETA/ETB antagonist (bosentan) at high altitudes
effectively controls the hypoxia-induced increase in pulmo-
nary blood pressure but also causes a reduction in free water
clearance. Besides the physiological implications regarding
the role of ET-1 at both the pulmonary and the renal district
in normal subjects, these findings appear to be of interest
because they might contribute to the definition of a therapeu-
tic window for the use of bosentan at high altitudes.
Pulmonary Effects of ET-1 Antagonism
The present findings clarify the role of ET-1 in pulmonary
hypertension at high altitudes in humans. In experimental
animals, exposure to acute hypoxia (48 hours of hypoxia at
10% O2, 1 atm) resulted in significant overexpression in the
lung of ET-1 peptide (1.5-fold) and of genes for ET-1 and
ETA receptor (4.1-fold and 2.3-fold, respectively), with
unchanged mRNA levels for the ETB receptor subtype.18
Overexpression of both ETA and ETB receptor genes was
observed in lung of rats exposed to chronic hypoxia (10% O2,
1 atm, 4 weeks).19 In rats exposed to normobaric hypoxia (90
minutes, 10% O2), the ETA receptor antagonist BQ-123
markedly attenuated the increase in pulmonary artery pres-
sure.20 Similar results were obtained after administration of
BMS-182874 (a selective ETA antagonist) in pigs subjected
to acute, intermittent 15-minute periods of hypoxia
(FiO20.1).21 Each of these experimental studies suggests
that ET-1 synthesized in lung in response to hypoxia acts
locally on ETA receptors to acutely increase pulmonary
pressure. In humans, indirect evidence was provided that
indicated that the increase in pulmonary pressure after expo-
Figure 2. Arterial oxygen saturation (left) and systolic pulmonary
artery pressure (right) at sea level (S.L.) and during exposure to
high altitude (days 0, 1, 2, and 3) in bosentan- () or placebo-
treated () group. *P0.05 vs placebo.
Figure 3. Relationship between arterial oxygen saturation (top)
or ET-1 plasma concentration (bottom) and systolic pulmonary
artery pressure.
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sure to high altitude is correlated with an increased plasma
ET-1 concentration.3,5,22 However, the pathogenetic role of
ET-1 for human pulmonary hypertension at high altitudes
remained to be investigated, and no studies reported the use
of ET receptor blockers as a possible prophylactic strategy.
In subjects exposed to high altitude in the present study,
administration of bosentan was associated not only with a
reduction in pulmonary pressure but also with an increase in
oxygen saturation. This is not in line with observations that
pulmonary vasoconstriction (and thus increases in pulmonary
pressure) in many pulmonary diseases optimizes the ratio of
alveolar ventilation to regional pulmonary perfusion and that
the therapeutic use of vasodilators (prostacyclin) increases
ventilation/perfusion mismatch and decreases arterial
oxygenation.23
It would be simplistic to consider that a reduction in
pulmonary pressure would necessarily correspond to changes
in ventilation/perfusion mismatch. This is because different
drugs that cause similar reductions in pulmonary arterial
pressure trigger different responses in arterial oxygenation. In
particular, in the setting of high-altitude–induced pulmonary
vasoconstriction, nitric oxide24 and sildenafil25 failed to
modify oxygen saturation, whereas in the present study, ET-1
antagonism by bosentan improved oxygen saturation. This
Figure 4. Urinary volume (left), free water
clearance (middle), and renal sodium
clearance (right) at sea level (S.L.) and
during exposure to high altitude (days 0,
1, 2, and 3) in bosentan- () or placebo-
treated () group. H2OCl indicates free
water clearance; NaCl, renal sodium
clearance. *P0.05 vs placebo.
TABLE 2. Renal Function and Segmental Tubular Function in Subjects Assigned to Bosentan or
Placebo-Treated Group at Sea Level and High Altitude
High Altitude
Sea Level Day 0 Day 1 Day 2 Day3
Urinary volume, mL
Placebo 1220610 1710540 1940620 1610590 1430470
Bosentan 1120250 1640350 1460260* 1100200* 1190270
Creatinine clearance, mL/min
Placebo 12513 12220 10723 10336 9237
Bosentan 12612 12117 10833 10913 10216
Free water clearance/creatinine clearance
Placebo 9.93.7 2.12.3 0.93.8 1.84.8 6.33.1
Bosentan 114.1 2.73.1 4.34.1 6.73.5* 6.85.1
Sodium clearance/creatinine clearance
Placebo 0.0060.005 0.0070.005 0.0110.006 0.0120.010 0.0110.006
Bosentan 0.0050.002 0.0060.002 0.0070.005 0.0070.003 0.0080.003
Lithium clearance/creatinine clearance
Placebo 0.140.04 0.130.05 0.100.02 0.200.11 0.180.05
Bosentan 0.140.05 0.150.05 0.130.05 0.170.09 0.160.11
Fractional proximal sodium reabsorption rate
(GFRLiCl)/GFR	
Placebo 0.860.05 0.870.05 0.900.02 0.800.11 0.820.05
Bosentan 0.860.05 0.850.05 0.870.05 0.830.09 0.840.11
Fractional distal sodium reabsorption
(LiClNaCl)/LiCl	
Placebo 0.950.04 0.950.02 0.900.05 0.930.05 0.930.06
Bosentan 0.960.02 0.960.01 0.940.05 0.950.03 0.930.05
*P0.05 vs placebo.
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response might highlight the importance of drug effects on
the pulmonary vein district, because pulmonary veins are
acknowledged as a main target only for ET-1.26 The control
of venoconstriction might thus more favorably reduce pul-
monary capillary pressure,3 ultimately preventing interstitial
edema and enhancing gas exchange even before the onset of
HAPE. In contrast, in subjects with clinically manifest
HAPE, the reduction of pulmonary arterial pressure could
have therapeutic effects per se, because in addition to inhaled
nitric oxide,24 other vasodilator agents, such as nifedipine,27
hydralazine, and phentolamine,28 were reported to improve
oxygen saturation.
Renal Effects of ET-1 Antagonism
The present study shows that exposure to high altitude is
followed by increased excretion of ET-1 in the urine. Plasma
and urinary ET-1 were reported to reflect the existence of
2 separate systems.15 Indeed, ET-1 excreted in the urine
does not derive from plasma, rather being locally produced
in the kidney.9,15 The second main result of the present
study is the clear demonstration that bosentan administra-
tion limited the physiological increase in free water clear-
ance observed at high altitude. An enhanced diuresis with
increased free water clearance is now considered a relevant
component of adaptation to altitude.8 This enhanced di-
uretic response was found to be associated with a reduction
in renal sensitivity to AVP even after 2 days of exposure to
high altitude,7 although conflicting results are available
with regard to changes in plasma concentration of AVP.
Convincing evidence exists that ET-1 may inhibit AVP-
stimulated water reabsorption in the collecting ducts.
Several studies have demonstrated that ET-1 binding to the
ETB receptor subtype reduces Na
-K
-ATPase activity
in the inner medullary collecting duct29 and inhibits
vasopressin-stimulated cAMP accumulation and water
transport on isolated cortical collecting ducts from rats.30,31
These and other studies32,33 indicate that ET-1 might
regulate water reabsorption independently of its effects on
Na
 reabsorption or renal hemodynamics. Only indirect
evidence of ET-1 effects on renal water handling in
humans was available until now.9 The present study clearly
indicates for the first time that the administration of a
mixed ET-1 receptor (ETA/ETB) antagonist in a condition
characterized by marked activation of renal ET-1 excretion
did not affect sodium excretion but rather reduced free
water clearance. Edema has been reported to occur in up to
20% of patients who undergo chronic bosentan treatment
for pulmonary hypertension, despite demonstration of a
reduction in right atrial pressure.34 Presumably, this is
related to a similar effect on renal function with a
reduction in free water clearance. An increased hypoxia-
induced atrial natriuretic peptide secretion was reported to
provide a further compensatory mechanism to modulate
the development of hypoxia-induced pulmonary hyperten-
sion and to regulate fluid balance during acute and chronic
exposure to hypoxia.35 In this condition, ET-1 produced in
the kidney appears to participate in the control of volume
by enhancing free water excretion, too.
According to a current theory in the field, the lack of
increase in urinary volume in the bosentan group should have
resulted in AMS. This did not appear to be the case in
subjects in the present study; however, it must be considered
that our study was neither sized or designed to investigate the
effects of bosentan on AMS symptoms. Indeed, the study
sample size was calculated on the basis of the hypothesized
effects of the drug on pulmonary pressure. In addition,
according to the study protocol, bosentan administration was
started after 1 day at altitude (day 1). The effects on diuresis
were observed at day 2, ie, at a time when a lower AMS score
was also already recorded in the placebo group. Thus,
although in theory, lack of urinary volume increase by
bosentan could be expected to favor AMS symptoms, we
were unable to detect such a phenomenon, probably because
of the concomitant beginning of subjects’ adaptation to
altitude, which might have reduced the sensitivity of our
assessment of changes in AMS symptoms. As an alternative
explanation, the study group may have been composed of
experienced mountaineers who were particularly resistant to
AMS.
A relevant clinical implication of the present study might
derive from the different timing of the pulmonary and renal
adaptive responses. Indeed, although pulmonary hypertension
was also significantly reduced after 3 days at altitude in the
group treated with placebo, a persistent increase in free water
clearance characterized the renal response. These different
patterns appear to reflect the different patterns of plasma and
renal ET-1 production. As a result of these differences, only
a short period of bosentan administration at high altitude
could be considered useful to control pulmonary hypertension
without impairing free water clearance in the long term. In
conclusion, compared with drugs that have already demon-
strated their efficacy in the field (such as nifedipine, silde-
nafil, or hydralazine), bosentan had potentially detrimental
effects on diuresis that may preclude its use as a pulmonary
artery pressure–lowering agent at high altitude. In particular,
if bosentan were proposed to prevent HAPE, its administra-
tion would need to be begun before the individual began to
climb at high altitude, and the resulting fluid retention might
not only precipitate AMS but also worsen alveolar fluid
flooding.
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CLINICAL PERSPECTIVE
The increase in pulmonary artery and capillary pressure that follows rapid ascent to high altitude without adequate
acclimatization may force liquid across the endothelial barrier into the interstitial space, with consequent respiratory
problems. Tens of thousands of tourists travel to a variety of high-altitude destinations around the world on a yearly basis,
so that notwithstanding the fact that different vasodilators have been found useful in the treatment of high-altitude
pulmonary edema, the search for new strategies to prevent high-altitude–induced pulmonary hypertension can be
considered a priority. In the present study, 1-day treatment with a mixed endothelin (ET)-1 receptor A and B antagonist
(bosentan) induced a significant reduction of systolic pulmonary artery pressure and a mild increase of arterial oxygen
saturation versus placebo in healthy subjects who rapidly ascended to the Regina Margherita hut (Monte Rosa, Italian Alps,
4559 m). The second main result of the study, however, is the clear demonstration that both urinary volume and free water
clearance were reduced significantly versus placebo after 2 days of ET-1 antagonism. Therefore, ET-1 participates in renal
fluid handling, and the early beneficial effect of bosentan on pulmonary hypertension is followed by potentially detrimental
effects on diuresis that may preclude its use as a pulmonary artery pressure–lowering agent at high altitude.
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